Milestone Pharmaceuticals Inc.
MIST- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001408443
No open-market purchases or sales by Milestone Pharmaceuticals Inc. insiders were filed in the last 90 days; 78 institutions reported holding it in 13F filings for Q2 2026, worth $68.1M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −7 vs. previous quarter
- 78
- 13F valueReported value at the end of Q2 2026
- $68.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding MIST, Q2 2026
No superinvestor reported holding MIST at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Milestone Pharmaceuticals Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 20, 2026 (view filing) | Apr 16 | 4 days | Oliveto JosephPresident and CEO | SSale | −36.5K | $2.26 | −$82.5K | −7.6%446.2K after | 10b5-1 |
| Jan 28, 2026 (view filing) | Dec 15, 2025-Jan 26, 2026 | 44 daysLate | Nelson Jeffrey EdwardChief Operating Officer | SSale | −70.3K | $2.25 | −$158.2K | −58.5%49.8K after | 2 lots |
| Jan 28, 2026 (view filing) | Dec 15, 2025-Jan 26, 2026 | 44 daysLate | Bharucha DavidChief Medical Officer | SSale | −70.3K | $2.25 | −$158.2K | −38.3%113.2K after | 2 lots |
| Jan 28, 2026 (view filing) | Dec 15, 2025-Jan 26, 2026 | 44 daysLate | Hasija AmitCFO & EVP of Corp. Development | SSale | −70.3K | $2.25 | −$158.2K | −41.3%99.8K after | 2 lots |
| Jan 28, 2026 (view filing) | Dec 15, 2025-Jan 26, 2026 | 44 daysLate | Muller LorenzChief Commercial Officer | SSale | −64.7K | $2.25 | −$145.9K | −24.0%205.4K after | 2 lots |
| Jan 28, 2026 (view filing) | Dec 15, 2025-Jan 26, 2026 | 44 daysLate | Oliveto JosephPresident and CEO | SSale | −167.6K | $2.24 | −$375.3K | −25.8%482.7K after | 2 lots |
| Jan 9, 2026 (view filing) | Jan 7-8 | 2 days | Oliveto JosephPresident and CEO | SSale | −43.5K | $2.25 | −$97.9K | −12.5%303.7K after | 2 lots10b5-1 |
| Dec 5, 2022 (view filing) | Dec 1-5 | 4 days | Bharucha DavidChief Medical Officer | PPurchase | +10.0K | $4.74 | +$47.4K | New position10.0K after | 2 lots |
| Oct 21, 2022 (view filing) | Oct 19 | 2 days | Wills Robert JamesDirector | PPurchase | +15.0K | $4.93 | +$74.0K | New position15.0K after | |
| Oct 21, 2022 (view filing) | Oct 20 | 1 day | Pasternak Richard CDirector | PPurchase | +10.0K | $5.20 | +$52.0K | New position10.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Milestone Pharmaceuticals Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Pavaki Capital Management LLC | 9,067,848 | $12.2M | 6.92% | +5,000+0.1% | Added |
| RTW Investments, LP | 7,833,336 | $10.5M | 0.09% | +1,502,335+23.7% | Added |
| Propel Bio Management, LLC | 7,429,590 | $9.96M | 5.21% | +3,311,269+80.4% | Added |
| Point72 Asset Management, L.P. | 5,411,138 | $7.25M | 0.01% | +4,325,455+398.4% | Added |
| Simplify Asset Management Inc. | 3,349,379 | $4.49M | 0.06% | +1,842,974+122.3% | Added |
| Millennium Management LLC | 3,142,219 | $4.21M | 0.00% | +1,597,894+103.5% | Added |
| Kalehua Capital Management LLC | 2,538,474 | $3.40M | 1.09% | +2,538,474 | New |
| Two Sigma Investments, LP | 2,040,015 | $2.73M | 0.00% | −277,161−12.0% | Reduced |
| Marshall Wace, LLP | 1,797,695 | $2.41M | 0.00% | −146,835−7.6% | Reduced |
| Lion Point Capital, LP | 820,000 | $1.10M | 5.26% | 00.0% | Unchanged |